Several years ago, Allegheny Health Network medical oncologist Casey Moffa had a patient who aggressively researched ways to avoid peripheral neuropathy — nerve damage in the fingers and toes that is a common side effect of the chemotherapy regimens used to treat breast cancer.
That patient, who needed full function in her fingers for her job, ended up submerging her fingers in ice water during her treatments. The treatment was successful in that she ultimately preserved full feeling in her hands.
Since that time, Moffa became aware of a product called SuzziPads, mittens and socks designed to keep extremities cold during chemotherapy. She recommended them to her patients, who had good results.
“Just anecdotally, if you looked at it, it was clearly working,” she said.
Now, local breast cancer patients won’t have to procure SuzziPads themselves. A new $33,000 grant from the McCandless-based Glimmer of Hope Foundation will cover SuzziPads for breast cancer patients at AHN’s largest breast cancer treatment sites, system wide. A similar $13,800 grant from Glimmer of Hope will cover breast cancer patients at UPMC Magee-Womens Hospital.
“It sounds like a small amount of money, but the impact, according to these oncologists, is really great,” said Diana Napper, founder and executive director of Glimmer of Hope. “We try to keep life as normal as possible for breast cancer patients. If we see something like this come along that we know will benefit patients, we do it.”
Peripheral neuropathy is the most common side effect of a class of chemotherapy drugs known as taxanes, which are often used to treat breast cancer. One study, published in the Journal of the National Cancer Institute in 2017, found that 42% of breast cancer patients treated with one of three common chemo drugs still experienced peripheral neuropathy side effects two years after the start of treatment, with 10% experiencing severe side effects.
Even at the time of treatment, peripheral neuropathy can be severe enough that doctors will cut back the dose or cut chemotherapy treatments short, said Moffa, especially when the numbness of pain travels up the fingertips into the hands or up the toes to the bottoms of the feet.
Breast cancer chemotherapy patients can also have other side effects in the fingernails, she said, where the nail lifts up and causes fingernail pain.
In the last couple of years, since Moffa started recommending that her patients use the SuzziPads during treatments, she has very rarely had to adjust a chemotherapy dose because of peripheral neuropathy. She tried to do a clinical trial to measure the difference scientifically, but didn’t have many patients willing to be in a control group and not use the cold pads.
There aren’t many large scientific studies on cold therapy for peripheral neuropathy. One Chinese study, published in the Annals of Medicine and Surgery in 2023, found that about half of participants who used cold therapy experienced peripheral neuropathy, versus more than 85% in the control groups. A 2025 review of multiple studies by researchers in Turkey, published in Seminars in Oncology Nursing, found cooling therapy to be effective in more than half of the studies reviewed.
The science behind using cooling therapy is that cold makes blood vessels smaller, limiting the amount of chemo drugs that reaches the hands and feet. It’s similar to the philosophy behind “cold capping,” the use of intense cold on the head to reduce the impact of chemotherapy on hair follicles to try to prevent hair loss.
The SuzziPads are filled with a gel that stays frozen for about 20 minutes, and can then be swapped for a freshly frozen gel pack. It is not particularly comfortable to wear freezing cold mittens and gloves during chemotherapy, said Moffa, but most patients are glad that they endured the cold to prevent side effects.
The pads are relatively affordable, at about $40 for a set, but Moffa is thankful that the grant will provide them to patients free of charge, lessening not just the financial burden but the mental load of procuring them.
“This is a hard thing for anyone to go through,” she said. “If we just have the ability to give it to them, it’s one less thing that they have to worry about. It will be a huge relief to a lot of patients.”







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.